{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:15Z","timestamp":1781643435507,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX003824"],"award-info":[{"award-number":["BX003824"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pathogenic alterations in NOTCH3 cause CADASIL, an accelerated and currently untreatable form of cerebrovascular disease. CADASIL mutant NOTCH3, which frequently harbors abnormalities in EGF repeat cysteine number, adopt disulfide dependent abnormal conformations. To seek potential strategies to mitigate the impact of CADASIL mutations on NOTCH3, we investigated whether cysteine-targeting compounds may affect pathological NOTCH3. LSL-NOTCH3, a split luciferase assay that discriminates between benign and pathogenic NOTCH3 conformations, was used to quantify the capacity of 21 small molecule compounds to restore NOTCH3 reporter activity. We assayed the activity of each of the small molecules on 16 different pathogenic mutants distributed over three different regions of NOTCH3. Ten of 21 compounds had statistically significant effects on at least one mutant NOTCH3. Five of 21 compounds had mitigating effects on a majority of mutant NOTCH3 in three regions of the protein, with disulfiram and auranofin targeting the most favorable range of mutants. These findings support the concept that cysteine-targeting can potentially mitigate the effects of a broad range of NOTCH3 pathogenic mutants and provide an impetus to investigate whether cysteine-targeting strategies affect disease-relevant phenotypes in EGF repeat-related human disorders.<\/jats:p>","DOI":"10.1038\/s41598-026-45103-1","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:24:21Z","timestamp":1773995061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants"],"prefix":"10.1038","volume":"16","author":[{"given":"Naw May Pearl","family":"Cartee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"45103_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/B978-0-444-64076-5.00047-8","volume":"148","author":"MM Wang","year":"2018","unstructured":"Wang, M. M. Cadasil. Handb. Clin. Neurol. 148, 733\u2013743. https:\/\/doi.org\/10.1016\/B978-0-444-64076-5.00047-8 (2018).","journal-title":"Handb. Clin. Neurol."},{"issue":"7","key":"45103_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1474-4422(09)70127-9","volume":"8","author":"H Chabriat","year":"2009","unstructured":"Chabriat, H., Joutel, A., Dichgans, M., Tournier-Lasserve, E. & Bousser, M. G. CADASIL. Lancet Neurol. 8(7), 643\u2013653. https:\/\/doi.org\/10.1016\/S1474-4422(09)70127-9 (2009) ((in eng)).","journal-title":"Lancet Neurol."},{"issue":"1-2","key":"45103_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jns.2015.01.018","volume":"349","author":"N Abramycheva","year":"2015","unstructured":"Abramycheva, N. et al. New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). J. Neurol. Sci. 349(1\u20132), 196\u2013201. https:\/\/doi.org\/10.1016\/j.jns.2015.01.018 (2015).","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"45103_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1212\/01.wnl.0000216259.99811.50","volume":"66","author":"Y Kim","year":"2006","unstructured":"Kim, Y. et al. Characteristics of CADASIL in Korea: A novel cysteine-sparing Notch3 mutation. Neurology 66(10), 1511\u20131516. https:\/\/doi.org\/10.1212\/01.wnl.0000216259.99811.50 (2006).","journal-title":"Neurology"},{"key":"45103_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091964","author":"E Mui\u00f1o","year":"2017","unstructured":"Mui\u00f1o, E. et al. Systematic review of cysteine-sparing NOTCH3 missense mutations in patients with clinical suspicion of CADASIL. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18091964 (2017) ((in eng)).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"45103_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/STROKEAHA.114.007472","volume":"46","author":"FA Wollenweber","year":"2015","unstructured":"Wollenweber, F. A. et al. Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro. Stroke 46(3), 786\u2013792. https:\/\/doi.org\/10.1161\/STROKEAHA.114.007472 (2015).","journal-title":"Stroke"},{"issue":"9","key":"45103_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/00005072-199709000-00001","volume":"56","author":"MM Ruchoux","year":"1997","unstructured":"Ruchoux, M. M. & Maurage, C. A. CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J. Neuropathol. Exp. Neurol. 56(9), 947\u2013964 (1997) ((in eng)).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"45103_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1172\/JCI8047","volume":"105","author":"A Joutel","year":"2000","unstructured":"Joutel, A. et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J. Clin. Invest. 105(5), 597\u2013605. https:\/\/doi.org\/10.1172\/JCI8047 (2000).","journal-title":"J. Clin. Invest."},{"key":"45103_CR9","doi-asserted-by":"publisher","unstructured":"F. Dabertrand et al. \"PIP,\" (in eng), Proc Natl Acad Sci U S A. 118 (17), https:\/\/doi.org\/10.1073\/pnas.2025998118 (2021).","DOI":"10.1073\/pnas.2025998118"},{"key":"45103_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104838","author":"SJ Lee","year":"2023","unstructured":"Lee, S. J. et al. Structural changes in NOTCH3 induced by CADASIL mutations: Role of cysteine and non-cysteine alterations. J. Biol. Chem. https:\/\/doi.org\/10.1016\/j.jbc.2023.104838 (2023) ((in eng)).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"45103_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108224","volume":"301","author":"NMP Cartee","year":"2025","unstructured":"Cartee, N. M. P. et al. Light-chain split luciferase assay implicates pathological NOTCH3 thiol reactivity in inherited cerebral small vessel disease. J. Biol. Chem. 301(3), 108224. https:\/\/doi.org\/10.1016\/j.jbc.2025.108224 (2025) ((in eng)).","journal-title":"J. Biol. Chem."},{"issue":"3","key":"45103_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41436-018-0088-3","volume":"21","author":"JW Rutten","year":"2019","unstructured":"Rutten, J. W. et al. The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1-6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7-34 pathogenic variant. Genet. Med. 21(3), 676\u2013682. https:\/\/doi.org\/10.1038\/s41436-018-0088-3 (2019) ((in eng)).","journal-title":"Genet. Med."},{"key":"45103_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac486","author":"RJ Hack","year":"2022","unstructured":"Hack, R. J. et al. Three-tiered EGFr domain risk stratification for individualized NOTCH3-small vessel disease prediction. Brain https:\/\/doi.org\/10.1093\/brain\/awac486 (2022) ((in eng)).","journal-title":"Brain"},{"key":"45103_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200744","author":"BPH Cho","year":"2022","unstructured":"Cho, B. P. H. et al. Association of NOTCH3 variant position with stroke onset and other clinical features among patients with CADASIL. Neurology https:\/\/doi.org\/10.1212\/WNL.0000000000200744 (2022) ((in eng)).","journal-title":"Neurology"},{"issue":"6333","key":"45103_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/352337a0","volume":"352","author":"HC Dietz","year":"1991","unstructured":"Dietz, H. C. et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352(6333), 337\u2013339. https:\/\/doi.org\/10.1038\/352337a0 (1991) ((in eng)).","journal-title":"Nature"},{"issue":"1","key":"45103_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03259-2","volume":"5","author":"KZ Young","year":"2022","unstructured":"Young, K. Z. et al. Oligomerization, trans-reduction, and instability of mutant NOTCH3 in inherited vascular dementia. Commun. Biol. 5(1), 331. https:\/\/doi.org\/10.1038\/s42003-022-03259-2 (2022) ((in eng)).","journal-title":"Commun. Biol."},{"key":"45103_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-3-030-80614-9_8","volume":"1348","author":"SM Zeigler","year":"2021","unstructured":"Zeigler, S. M., Sloan, B. & Jones, J. A. \u201cPathophysiology and Pathogenesis of Marfan Syndrome,\u201d (in eng). Adv. Exp. Med. Biol. 1348, 185\u2013206. https:\/\/doi.org\/10.1007\/978-3-030-80614-9_8 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"13","key":"45103_CR18","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.7150\/ijms.60685","volume":"18","author":"Q Du","year":"2021","unstructured":"Du, Q. et al. The molecular genetics of Marfan syndrome. Int. J. Med. Sci. 18(13), 2752\u20132766. https:\/\/doi.org\/10.7150\/ijms.60685 (2021) ((in eng)).","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"45103_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108159","volume":"301","author":"LQ Bars\u00e9","year":"2025","unstructured":"Bars\u00e9, L. Q. et al. Auranofin induces disulfide bond-mimicking S-Au adducts in protein thiol pairs. J. Biol. Chem. 301(3), 108159. https:\/\/doi.org\/10.1016\/j.jbc.2025.108159 (2025) ((in eng)).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"45103_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder, C. & Thomson, M. J. Auranofin: Repurposing an old drug for a golden new age. Drugs R D 15(1), 13\u201320. https:\/\/doi.org\/10.1007\/s40268-015-0083-y (2015) ((in eng)).","journal-title":"Drugs R D"},{"issue":"2","key":"45103_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1006\/bbrc.2001.6027","volume":"289","author":"JS Yakisich","year":"2001","unstructured":"Yakisich, J. S., Sid\u00e9n, A., Eneroth, P. & Cruz, M. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem. Biophys. Res. Commun. 289(2), 586\u2013590. https:\/\/doi.org\/10.1006\/bbrc.2001.6027 (2001) ((in eng)).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"17","key":"45103_CR22","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1111\/j.1742-4658.2009.07189.x","volume":"276","author":"F Malka","year":"2009","unstructured":"Malka, F., Dairou, J., Ragunathan, N., Dupret, J. M. & Rodrigues-Lima, F. Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram. FEBS J. 276(17), 4900\u20134908. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07189.x (2009) ((in eng)).","journal-title":"FEBS J."},{"issue":"3","key":"45103_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/carcin\/bgt366","volume":"35","author":"A Paranjpe","year":"2014","unstructured":"Paranjpe, A., Zhang, R., Ali-Osman, F., Bobustuc, G. C. & Srivenugopal, K. S. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35(3), 692\u2013702. https:\/\/doi.org\/10.1093\/carcin\/bgt366 (2014) ((in eng)).","journal-title":"Carcinogenesis"},{"key":"45103_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01752-25","author":"T Xu","year":"2025","unstructured":"Xu, T., Luan, J., Hou, Y. & Zhang, L. Disulfiram inhibits poxvirus extracellular virus production by targeting the palmitoylation sites on F13. Microbiol. Spectr. https:\/\/doi.org\/10.1128\/spectrum.01752-25 (2025) ((in eng)).","journal-title":"Microbiol. Spectr."},{"issue":"6","key":"45103_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1021\/mp049917l","volume":"1","author":"TW Loo","year":"2004","unstructured":"Loo, T. W., Bartlett, M. C. & Clarke, D. M. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol. Pharm. 1(6), 426\u2013433. https:\/\/doi.org\/10.1021\/mp049917l (2004) ((in eng)).","journal-title":"Mol. Pharm."},{"issue":"1","key":"45103_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60068-x","volume":"16","author":"C Tian","year":"2025","unstructured":"Tian, C. et al. Proteome-wide ligandability maps of drugs with diverse cysteine-reactive chemotypes. Nat. Commun. 16(1), 4863. https:\/\/doi.org\/10.1038\/s41467-025-60068-x (2025) ((in eng)).","journal-title":"Nat. Commun."},{"issue":"6","key":"45103_CR27","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1007\/s12035-021-02282-4","volume":"58","author":"A Manini","year":"2021","unstructured":"Manini, A. & Pantoni, L. CADASIL from bench to bedside: Disease models and novel therapeutic approaches. Mol. Neurobiol. 58(6), 2558\u20132573. https:\/\/doi.org\/10.1007\/s12035-021-02282-4 (2021) ((in eng)).","journal-title":"Mol. Neurobiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45103-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45103-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45103-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:32:55Z","timestamp":1781641975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45103-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45103"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45103-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14300"}}